Iterum Therapeutics plc (ITRM)
NASDAQ: ITRM · Real-Time Price · USD
0.7095
-0.0125 (-1.73%)
Aug 28, 2025, 12:37 PM - Market open
Iterum Therapeutics Employees
Iterum Therapeutics had 9 employees as of December 31, 2024. The number of employees decreased by 5 or -35.71% compared to the previous year.
Employees
9
Change (1Y)
-5
Growth (1Y)
-35.71%
Revenue / Employee
n/a
Profits / Employee
-$2,675,111
Market Cap
31.68M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 9 | -5 | -35.71% |
Dec 31, 2023 | 14 | 0 | - |
Dec 31, 2022 | 14 | 1 | 7.69% |
Dec 31, 2021 | 13 | 6 | 85.71% |
Dec 31, 2020 | 7 | -37 | -84.09% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
ITRM News
- 8 days ago - Iterum Therapeutics launches ORLYNVAH™, the first and only oral penem antibiotic in the U.S. - GlobeNewsWire
- 22 days ago - Iterum Therapeutics plc (ITRM) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 23 days ago - Iterum Therapeutics Reports Second Quarter 2025 Financial Results - GlobeNewsWire
- 4 weeks ago - Iterum Therapeutics to Report Second Quarter 2025 Financial Results on August 5, 2025 - GlobeNewsWire
- 2 months ago - Iterum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 2 months ago - Iterum Names Christine Coyne as Chief Commercial Officer to Lead ORLYNVAH™ Launch and Commercial Growth - GlobeNewsWire
- 2 months ago - Iterum Therapeutics Announces Publication of REASSURE Trial in NEJM Evidence - GlobeNewsWire
- 2 months ago - Iterum Therapeutics Announces Partnership for Commercialization Services - GlobeNewsWire